Work

Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-207476

Authors: Jennifer Croden, Danielle Hammond, Kelly S. Chien, Abhishek Maiti, George Donovan Tippett, Guillermo Montalban-Bravo, Michael Morales, Nicholas J. Short, Hussein A. Abbas, Ghayas C. Issa, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405038619

Cites:

Cited by: 4

Related to: 10